Talking about Viral Suppression and HIV Transmission Webinars: September 15 & 19

Content From: Nathan Fecik, MPH, Public Health Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human ServicesPublished: September 11, 20172 min read

Topics

picture-of-computer-screen-with-the-word-webinar.jpg

We want to hear your thoughts!

The HHS Office of HIV/AIDS and Infectious Disease Policy will host two listening sessions this month to discuss the work that HHS has been doing to review the game-changing studies on the impact of HIV antiretroviral treatment (ART) and viral suppression on the sexual transmission of HIV. These studies followed approximately 3,000 sexually active mixed HIV-status couples over many years—and observed no HIV transmissions while the HIV-positive partner was taking ART and virally suppressed.

During the listening sessions we’ll be sharing information with you about the work HHS agencies and offices have done recently to review these studies and develop draft messages for use in a wide variety of communications (e.g., websites, materials, tools, campaigns, etc.). We would like to get your thoughts on these draft messages and how they might be improved. Specifically we want to hear from you to:

  • Get your thoughts about the draft messages and how you think they may be received by those you serve and anything that might be confusing or problematic

  • Identify any specific issues you or others may have about the messages and obtain your input on how best to respond to them

For more information on the listening sessions and to register, please follow the links below:

  1. Community leaders and stakeholders, people living with HIV, and those who are at risk for HIV infection

Friday, September 15, 2017 from 3:00-4:00 pm ET

  1. Healthcare providers, state and local health departments, and other government agencies

Tuesday, September 19, 2017 from 3:00-4:00 pm ET

Read more about updates to HHS agency messages on this topic.

View a Facebook Live conversation that OHAIDP’s Director, Dr. Rich Wolitski, held last week at the 2017 U.S. Conference on AIDS about this topic with several HIV-positive friends and HIV community leaders.